Kolmar BioTech콜마바이오텍
215380 · KOSDAQ · ₩215380 · 콜마바이오텍
₩2,045▼ ₩80 (3.76%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 30.2% | 26.9% | 29.4% | 16.3% | 14.3% | 18.8% |
| Operating margin | −1.1% | −10.4% | 4.1% | −11.5% | −5.4% | −11.3% |
| Net margin | 2.8% | −14.8% | 0.5% | −13.1% | −4.0% | −6.2% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +17.6% | −13.0% | +11.9% | −17.7% | +50.2% | — |
| Operating income growth | +87.8% | −318.8% | +140.0% | −76.9% | +28.5% | — |
| Net income growth | +122.3% | −2,561.9% | +104.5% | −168.8% | +2.4% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 4.9% | −21.0% | 0.9% | −19.6% | −6.1% | −6.1% |
| Return on assets | 1.3% | −6.1% | 0.2% | −5.2% | −1.9% | −1.9% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 288.6% | 271.3% | 222.4% | 347.5% | 219.6% | 218.3% |
| Net debt to equity | 65.2% | 197.1% | 156.9% | 204.4% | 123.5% | 120.3% |
| Current ratio | 54.6% | 57.0% | 63.6% | 43.1% | 30.7% | 66.2% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Kolmar BioTech / 콜마바이오텍 / 215380 / KRX:215380
Source: KRX statistical information